Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Biopharma, will present an overview of the company and highlight recent events, including the FDA approval of Recorlev®, at the H.C. Wainwright BioConnect 2022 virtual conference being held January 10-13, 2022.

The on-demand presentation will be available beginning January 10, 2022 at 7:00 a.m. E.T. through the investors section on the Company’s website at www.xerispharma.com.

About Xeris Biopharma

Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has two commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis. In addition, Recorlev® was recently approved by the U.S. Food and Drug Administration for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.

Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005180/en/